CN111333715B - 一种类i型胶原蛋白纤维的制备方法 - Google Patents
一种类i型胶原蛋白纤维的制备方法 Download PDFInfo
- Publication number
- CN111333715B CN111333715B CN202010327199.4A CN202010327199A CN111333715B CN 111333715 B CN111333715 B CN 111333715B CN 202010327199 A CN202010327199 A CN 202010327199A CN 111333715 B CN111333715 B CN 111333715B
- Authority
- CN
- China
- Prior art keywords
- gly
- pro
- collagen
- glu
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000835 fiber Substances 0.000 title claims abstract description 57
- 102000012422 Collagen Type I Human genes 0.000 title claims abstract description 33
- 108010022452 Collagen Type I Proteins 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 102000008186 Collagen Human genes 0.000 claims abstract description 100
- 108010035532 Collagen Proteins 0.000 claims abstract description 100
- 229920001436 collagen Polymers 0.000 claims abstract description 99
- GVVPGTZRZFNKDS-JXMROGBWSA-N geranyl diphosphate Chemical compound CC(C)=CCC\C(C)=C\CO[P@](O)(=O)OP(O)(O)=O GVVPGTZRZFNKDS-JXMROGBWSA-N 0.000 claims abstract description 16
- 238000000034 method Methods 0.000 claims abstract description 13
- 238000001338 self-assembly Methods 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 45
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 239000013612 plasmid Substances 0.000 claims description 17
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 241000588724 Escherichia coli Species 0.000 claims description 10
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 238000004220 aggregation Methods 0.000 claims description 4
- 229940096422 collagen type i Drugs 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000012264 purified product Substances 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 abstract description 10
- 239000012620 biological material Substances 0.000 abstract description 6
- 210000004899 c-terminal region Anatomy 0.000 abstract description 5
- 238000010353 genetic engineering Methods 0.000 abstract description 2
- 230000003993 interaction Effects 0.000 abstract description 2
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 43
- 108010014614 prolyl-glycyl-proline Proteins 0.000 description 33
- OOCFXNOVSLSHAB-IUCAKERBSA-N Gly-Pro-Pro Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 OOCFXNOVSLSHAB-IUCAKERBSA-N 0.000 description 28
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 26
- CAVKXZMMDNOZJU-UHFFFAOYSA-N Gly-Pro-Ala-Gly-Pro Natural products C1CCC(C(O)=O)N1C(=O)CNC(=O)C(C)NC(=O)C1CCCN1C(=O)CN CAVKXZMMDNOZJU-UHFFFAOYSA-N 0.000 description 25
- AAORVPFVUIHEAB-YUMQZZPRSA-N Lys-Asp-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O AAORVPFVUIHEAB-YUMQZZPRSA-N 0.000 description 25
- 108010078144 glutaminyl-glycine Proteins 0.000 description 24
- 108010029020 prolylglycine Proteins 0.000 description 23
- LOEANKRDMMVOGZ-YUMQZZPRSA-N Gly-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O LOEANKRDMMVOGZ-YUMQZZPRSA-N 0.000 description 20
- NLKVNZUFDPWPNL-YUMQZZPRSA-N Glu-Arg-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O NLKVNZUFDPWPNL-YUMQZZPRSA-N 0.000 description 18
- 108010002311 N-glycylglutamic acid Proteins 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 108010038633 aspartylglutamate Proteins 0.000 description 17
- 108010003700 lysyl aspartic acid Proteins 0.000 description 17
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 17
- BRPMXFSTKXXNHF-IUCAKERBSA-N (2s)-1-[2-[[(2s)-pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1NCCC1 BRPMXFSTKXXNHF-IUCAKERBSA-N 0.000 description 15
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 14
- 108010015792 glycyllysine Proteins 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- FGYPOQPQTUNESW-IUCAKERBSA-N Gln-Gly-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CCC(=O)N)N FGYPOQPQTUNESW-IUCAKERBSA-N 0.000 description 12
- 108010044940 alanylglutamine Proteins 0.000 description 12
- 108010047857 aspartylglycine Proteins 0.000 description 12
- 230000005540 biological transmission Effects 0.000 description 12
- 108010004914 prolylarginine Proteins 0.000 description 12
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 11
- DHDOADIPGZTAHT-YUMQZZPRSA-N Gly-Glu-Arg Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N DHDOADIPGZTAHT-YUMQZZPRSA-N 0.000 description 11
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 11
- UCBPDSYUVAAHCD-UWVGGRQHSA-N Leu-Pro-Gly Chemical compound CC(C)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UCBPDSYUVAAHCD-UWVGGRQHSA-N 0.000 description 11
- KIZQGKLMXKGDIV-BQBZGAKWSA-N Pro-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 KIZQGKLMXKGDIV-BQBZGAKWSA-N 0.000 description 11
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 11
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 10
- PZXPWHFYZXTFBI-YUMQZZPRSA-N Asp-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PZXPWHFYZXTFBI-YUMQZZPRSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- HFXJIZNEXNIZIJ-BQBZGAKWSA-N Gly-Glu-Gln Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFXJIZNEXNIZIJ-BQBZGAKWSA-N 0.000 description 10
- UIMCLYYSUCIUJM-UWVGGRQHSA-N Pro-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 UIMCLYYSUCIUJM-UWVGGRQHSA-N 0.000 description 10
- MSIYNSBKKVMGFO-BHNWBGBOSA-N Thr-Gly-Pro Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N)O MSIYNSBKKVMGFO-BHNWBGBOSA-N 0.000 description 10
- 108010047495 alanylglycine Proteins 0.000 description 10
- 108010061238 threonyl-glycine Proteins 0.000 description 10
- MDNAVFBZPROEHO-UHFFFAOYSA-N Ala-Lys-Val Natural products CC(C)C(C(O)=O)NC(=O)C(NC(=O)C(C)N)CCCCN MDNAVFBZPROEHO-UHFFFAOYSA-N 0.000 description 9
- RKNIUWSZIAUEPK-PBCZWWQYSA-N Asp-His-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CC(=O)O)N)O RKNIUWSZIAUEPK-PBCZWWQYSA-N 0.000 description 9
- RZSLYUUFFVHFRQ-FXQIFTODSA-N Gln-Ala-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O RZSLYUUFFVHFRQ-FXQIFTODSA-N 0.000 description 9
- CGYDXNKRIMJMLV-GUBZILKMSA-N Glu-Arg-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O CGYDXNKRIMJMLV-GUBZILKMSA-N 0.000 description 9
- JVSBYEDSSRZQGV-GUBZILKMSA-N Glu-Asp-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCC(O)=O JVSBYEDSSRZQGV-GUBZILKMSA-N 0.000 description 9
- PXHABOCPJVTGEK-BQBZGAKWSA-N Glu-Gln-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O PXHABOCPJVTGEK-BQBZGAKWSA-N 0.000 description 9
- HVYWQYLBVXMXSV-GUBZILKMSA-N Glu-Leu-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O HVYWQYLBVXMXSV-GUBZILKMSA-N 0.000 description 9
- XMPXVJIDADUOQB-RCOVLWMOSA-N Gly-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)CNC(=O)C[NH3+] XMPXVJIDADUOQB-RCOVLWMOSA-N 0.000 description 9
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 description 9
- HJARVELKOSZUEW-YUMQZZPRSA-N Gly-Pro-Gln Chemical compound [H]NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O HJARVELKOSZUEW-YUMQZZPRSA-N 0.000 description 9
- VSLXGYMEHVAJBH-DLOVCJGASA-N His-Ala-Leu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O VSLXGYMEHVAJBH-DLOVCJGASA-N 0.000 description 9
- GECLQMBTZCPAFY-PEFMBERDSA-N Ile-Gln-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)O)N GECLQMBTZCPAFY-PEFMBERDSA-N 0.000 description 9
- LAPSXOAUPNOINL-YUMQZZPRSA-N Leu-Gly-Asp Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O LAPSXOAUPNOINL-YUMQZZPRSA-N 0.000 description 9
- LVTJJOJKDCVZGP-QWRGUYRKSA-N Leu-Lys-Gly Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O LVTJJOJKDCVZGP-QWRGUYRKSA-N 0.000 description 9
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 description 9
- BNBBNGZZKQUWCD-IUCAKERBSA-N Pro-Arg-Gly Chemical compound NC(N)=NCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 BNBBNGZZKQUWCD-IUCAKERBSA-N 0.000 description 9
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 description 9
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 9
- 108010091092 arginyl-glycyl-proline Proteins 0.000 description 9
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 9
- 108010054666 glycyl-leucyl-glycyl-glycine Proteins 0.000 description 9
- 108010026333 seryl-proline Proteins 0.000 description 9
- ZVFVBBGVOILKPO-WHFBIAKZSA-N Ala-Gly-Ala Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O ZVFVBBGVOILKPO-WHFBIAKZSA-N 0.000 description 8
- WVNFNPGXYADPPO-BQBZGAKWSA-N Arg-Gly-Ser Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O WVNFNPGXYADPPO-BQBZGAKWSA-N 0.000 description 8
- AUZAXCPWMDBWEE-HJGDQZAQSA-N Arg-Thr-Glu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O AUZAXCPWMDBWEE-HJGDQZAQSA-N 0.000 description 8
- QCVXMEHGFUMKCO-YUMQZZPRSA-N Asp-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O QCVXMEHGFUMKCO-YUMQZZPRSA-N 0.000 description 8
- WQWMZOIPXWSZNE-WDSKDSINSA-N Gln-Asp-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O WQWMZOIPXWSZNE-WDSKDSINSA-N 0.000 description 8
- XHUCVVHRLNPZSZ-CIUDSAMLSA-N Glu-Gln-Glu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O XHUCVVHRLNPZSZ-CIUDSAMLSA-N 0.000 description 8
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 8
- KZTLOHBDLMIFSH-XVYDVKMFSA-N His-Ala-Asp Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(O)=O KZTLOHBDLMIFSH-XVYDVKMFSA-N 0.000 description 8
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 8
- AUBMZAMQCOYSIC-MNXVOIDGSA-N Leu-Ile-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O AUBMZAMQCOYSIC-MNXVOIDGSA-N 0.000 description 8
- IEWBEPKLKUXQBU-VOAKCMCISA-N Leu-Leu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O IEWBEPKLKUXQBU-VOAKCMCISA-N 0.000 description 8
- FDBTVENULFNTAL-XQQFMLRXSA-N Leu-Val-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N FDBTVENULFNTAL-XQQFMLRXSA-N 0.000 description 8
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 description 8
- RIJCHEVHFWMDKD-SRVKXCTJSA-N Lys-Lys-Asn Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O RIJCHEVHFWMDKD-SRVKXCTJSA-N 0.000 description 8
- IHRFZLQEQVHXFA-RHYQMDGZSA-N Met-Thr-Lys Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCCN IHRFZLQEQVHXFA-RHYQMDGZSA-N 0.000 description 8
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 8
- XOHJOMKCRLHGCY-UNQGMJICSA-N Phe-Pro-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOHJOMKCRLHGCY-UNQGMJICSA-N 0.000 description 8
- WMZVVNLPHFSUPA-BPUTZDHNSA-N Ser-Trp-Arg Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 WMZVVNLPHFSUPA-BPUTZDHNSA-N 0.000 description 8
- 108010062796 arginyllysine Proteins 0.000 description 8
- BLIMFWGRQKRCGT-YUMQZZPRSA-N Ala-Gly-Lys Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCCN BLIMFWGRQKRCGT-YUMQZZPRSA-N 0.000 description 7
- HAFCJCDJGIOYPW-WDSKDSINSA-N Asp-Gly-Gln Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O HAFCJCDJGIOYPW-WDSKDSINSA-N 0.000 description 7
- BMWFDYIYBAFROD-WPRPVWTQSA-N Gly-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN BMWFDYIYBAFROD-WPRPVWTQSA-N 0.000 description 7
- 108010064235 lysylglycine Proteins 0.000 description 7
- 238000001000 micrograph Methods 0.000 description 7
- BEMGNWZECGIJOI-WDSKDSINSA-N Ala-Gly-Glu Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O BEMGNWZECGIJOI-WDSKDSINSA-N 0.000 description 6
- OQCWXQJLCDPRHV-UWVGGRQHSA-N Arg-Gly-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O OQCWXQJLCDPRHV-UWVGGRQHSA-N 0.000 description 6
- NSORZJXKUQFEKL-JGVFFNPUSA-N Gln-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCC(=O)N)N)C(=O)O NSORZJXKUQFEKL-JGVFFNPUSA-N 0.000 description 6
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 6
- MVBZBRKNZVJEKK-DTWKUNHWSA-N Met-Gly-Pro Chemical compound CSCC[C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N MVBZBRKNZVJEKK-DTWKUNHWSA-N 0.000 description 6
- 108010079364 N-glycylalanine Proteins 0.000 description 6
- 241000193996 Streptococcus pyogenes Species 0.000 description 6
- 238000002983 circular dichroism Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- IFTVANMRTIHKML-WDSKDSINSA-N Ala-Gln-Gly Chemical compound C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O IFTVANMRTIHKML-WDSKDSINSA-N 0.000 description 5
- VIRHEUMYXXLCBF-WDSKDSINSA-N Asp-Gly-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O VIRHEUMYXXLCBF-WDSKDSINSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- JBRBACJPBZNFMF-YUMQZZPRSA-N Gly-Ala-Lys Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN JBRBACJPBZNFMF-YUMQZZPRSA-N 0.000 description 5
- MOJKRXIRAZPZLW-WDSKDSINSA-N Gly-Glu-Ala Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MOJKRXIRAZPZLW-WDSKDSINSA-N 0.000 description 5
- MBOAPAXLTUSMQI-JHEQGTHGSA-N Gly-Glu-Thr Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MBOAPAXLTUSMQI-JHEQGTHGSA-N 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 5
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 5
- UCTIUWKCVNGEFH-OBJOEFQTSA-N Pro-Val-Gly-Pro Chemical compound N([C@@H](C(C)C)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C(=O)[C@@H]1CCCN1 UCTIUWKCVNGEFH-OBJOEFQTSA-N 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000013256 coordination polymer Substances 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 5
- 108010010147 glycylglutamine Proteins 0.000 description 5
- 108010050848 glycylleucine Proteins 0.000 description 5
- 108010057821 leucylproline Proteins 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- QHASENCZLDHBGX-ONGXEEELSA-N Ala-Gly-Phe Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 QHASENCZLDHBGX-ONGXEEELSA-N 0.000 description 4
- NONSEUUPKITYQT-BQBZGAKWSA-N Arg-Asn-Gly Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)O)N)CN=C(N)N NONSEUUPKITYQT-BQBZGAKWSA-N 0.000 description 4
- ZATRYQNPUHGXCU-DTWKUNHWSA-N Arg-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CCCN=C(N)N)N)C(=O)O ZATRYQNPUHGXCU-DTWKUNHWSA-N 0.000 description 4
- ZPDVKYLJTOFQJV-WDSKDSINSA-N Gln-Asn-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(O)=O ZPDVKYLJTOFQJV-WDSKDSINSA-N 0.000 description 4
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 4
- BULIVUZUDBHKKZ-WDSKDSINSA-N Gly-Gln-Asn Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O BULIVUZUDBHKKZ-WDSKDSINSA-N 0.000 description 4
- GLACUWHUYFBSPJ-FJXKBIBVSA-N Gly-Pro-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CN GLACUWHUYFBSPJ-FJXKBIBVSA-N 0.000 description 4
- DPWGZWUMUUJQDT-IUCAKERBSA-N Leu-Gln-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O DPWGZWUMUUJQDT-IUCAKERBSA-N 0.000 description 4
- ZPPVJIJMIKTERM-YUMQZZPRSA-N Pro-Gln-Gly Chemical compound OC(=O)CNC(=O)[C@H](CCC(=O)N)NC(=O)[C@@H]1CCCN1 ZPPVJIJMIKTERM-YUMQZZPRSA-N 0.000 description 4
- VYWNORHENYEQDW-YUMQZZPRSA-N Pro-Gly-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 VYWNORHENYEQDW-YUMQZZPRSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 4
- 108010027234 aspartyl-glycyl-glutamyl-alanine Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 108010049041 glutamylalanine Proteins 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002194 synthesizing effect Effects 0.000 description 4
- CUVSTAMIHSSVKL-UWVGGRQHSA-N (4s)-4-[(2-aminoacetyl)amino]-5-[[(2s)-6-amino-1-(carboxymethylamino)-1-oxohexan-2-yl]amino]-5-oxopentanoic acid Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN CUVSTAMIHSSVKL-UWVGGRQHSA-N 0.000 description 3
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 3
- SUHLZMHFRALVSY-YUMQZZPRSA-N Ala-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)NCC(O)=O SUHLZMHFRALVSY-YUMQZZPRSA-N 0.000 description 3
- AXXCUABIFZPKPM-BQBZGAKWSA-N Asp-Arg-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O AXXCUABIFZPKPM-BQBZGAKWSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- VSXBYIJUAXPAAL-WDSKDSINSA-N Gln-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](N)CCC(N)=O VSXBYIJUAXPAAL-WDSKDSINSA-N 0.000 description 3
- GPSHCSTUYOQPAI-JHEQGTHGSA-N Glu-Thr-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O GPSHCSTUYOQPAI-JHEQGTHGSA-N 0.000 description 3
- PUUYVMYCMIWHFE-BQBZGAKWSA-N Gly-Ala-Arg Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PUUYVMYCMIWHFE-BQBZGAKWSA-N 0.000 description 3
- KKBWDNZXYLGJEY-UHFFFAOYSA-N Gly-Arg-Pro Natural products NCC(=O)NC(CCNC(=N)N)C(=O)N1CCCC1C(=O)O KKBWDNZXYLGJEY-UHFFFAOYSA-N 0.000 description 3
- TWTPDFFBLQEBOE-IUCAKERBSA-N Gly-Leu-Gln Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O TWTPDFFBLQEBOE-IUCAKERBSA-N 0.000 description 3
- IEGFSKKANYKBDU-QWHCGFSZSA-N Gly-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)CN)C(=O)O IEGFSKKANYKBDU-QWHCGFSZSA-N 0.000 description 3
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- CLNJSLSHKJECME-BQBZGAKWSA-N Pro-Gly-Ala Chemical compound OC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1 CLNJSLSHKJECME-BQBZGAKWSA-N 0.000 description 3
- AFXCXDQNRXTSBD-FJXKBIBVSA-N Pro-Gly-Thr Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O AFXCXDQNRXTSBD-FJXKBIBVSA-N 0.000 description 3
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 238000012772 sequence design Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000012137 tryptone Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- SCAKQYSGEIHPLV-IUCAKERBSA-N (4S)-4-[(2-aminoacetyl)amino]-5-[(2S)-2-(carboxymethylcarbamoyl)pyrrolidin-1-yl]-5-oxopentanoic acid Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O SCAKQYSGEIHPLV-IUCAKERBSA-N 0.000 description 2
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 2
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 2
- VXKCPBPQEKKERH-IUCAKERBSA-N Gly-Arg-Pro Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N1CCC[C@H]1C(O)=O VXKCPBPQEKKERH-IUCAKERBSA-N 0.000 description 2
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 2
- WDEHMRNSGHVNOH-VHSXEESVSA-N Gly-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)CN)C(=O)O WDEHMRNSGHVNOH-VHSXEESVSA-N 0.000 description 2
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 2
- 239000012880 LB liquid culture medium Substances 0.000 description 2
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 2
- GPJGFSFYBJGYRX-YUMQZZPRSA-N Lys-Gly-Asp Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O GPJGFSFYBJGYRX-YUMQZZPRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- WIPAMEKBSHNFQE-IUCAKERBSA-N Pro-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@@H]1CCCN1 WIPAMEKBSHNFQE-IUCAKERBSA-N 0.000 description 2
- UHBPFYOQQPFKQR-JHEQGTHGSA-N Thr-Gln-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O UHBPFYOQQPFKQR-JHEQGTHGSA-N 0.000 description 2
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011033 desalting Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- -1 tissue engineering Substances 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WDIYWDJLXOCGRW-ACZMJKKPSA-N Ala-Asp-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O WDIYWDJLXOCGRW-ACZMJKKPSA-N 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- HGKHPCFTRQDHCU-IUCAKERBSA-N Arg-Pro-Gly Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O HGKHPCFTRQDHCU-IUCAKERBSA-N 0.000 description 1
- ZJIFRAPZHAGLGR-MELADBBJSA-N Asn-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)N)N)C(=O)O ZJIFRAPZHAGLGR-MELADBBJSA-N 0.000 description 1
- XHTUGJCAEYOZOR-UBHSHLNASA-N Asn-Ser-Trp Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O XHTUGJCAEYOZOR-UBHSHLNASA-N 0.000 description 1
- JJQGZGOEDSSHTE-FOHZUACHSA-N Asp-Thr-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O JJQGZGOEDSSHTE-FOHZUACHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 1
- VGTDBGYFVWOQTI-RYUDHWBXSA-N Gln-Gly-Phe Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VGTDBGYFVWOQTI-RYUDHWBXSA-N 0.000 description 1
- BJPPYOMRAVLXBY-YUMQZZPRSA-N Gln-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N BJPPYOMRAVLXBY-YUMQZZPRSA-N 0.000 description 1
- SJPMNHCEWPTRBR-BQBZGAKWSA-N Glu-Glu-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O SJPMNHCEWPTRBR-BQBZGAKWSA-N 0.000 description 1
- VGBSZQSKQRMLHD-MNXVOIDGSA-N Glu-Leu-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VGBSZQSKQRMLHD-MNXVOIDGSA-N 0.000 description 1
- HRBYTAIBKPNZKQ-AVGNSLFASA-N Glu-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O HRBYTAIBKPNZKQ-AVGNSLFASA-N 0.000 description 1
- CQAHWYDHKUWYIX-YUMQZZPRSA-N Glu-Pro-Gly Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O CQAHWYDHKUWYIX-YUMQZZPRSA-N 0.000 description 1
- GZUKEVBTYNNUQF-WDSKDSINSA-N Gly-Ala-Gln Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GZUKEVBTYNNUQF-WDSKDSINSA-N 0.000 description 1
- QXPRJQPCFXMCIY-NKWVEPMBSA-N Gly-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN QXPRJQPCFXMCIY-NKWVEPMBSA-N 0.000 description 1
- PMNHJLASAAWELO-FOHZUACHSA-N Gly-Asp-Thr Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PMNHJLASAAWELO-FOHZUACHSA-N 0.000 description 1
- CLNSYANKYVMZNM-UWVGGRQHSA-N Gly-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CCCN=C(N)N CLNSYANKYVMZNM-UWVGGRQHSA-N 0.000 description 1
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 1
- JBCLFWXMTIKCCB-UHFFFAOYSA-N H-Gly-Phe-OH Natural products NCC(=O)NC(C(O)=O)CC1=CC=CC=C1 JBCLFWXMTIKCCB-UHFFFAOYSA-N 0.000 description 1
- 108010065920 Insulin Lispro Proteins 0.000 description 1
- RNKSNIBMTUYWSH-YFKPBYRVSA-N L-prolylglycine Chemical compound [O-]C(=O)CNC(=O)[C@@H]1CCC[NH2+]1 RNKSNIBMTUYWSH-YFKPBYRVSA-N 0.000 description 1
- WSXTWLJHTLRFLW-SRVKXCTJSA-N Lys-Ala-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O WSXTWLJHTLRFLW-SRVKXCTJSA-N 0.000 description 1
- GAOJCVKPIGHTGO-UWVGGRQHSA-N Lys-Arg-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O GAOJCVKPIGHTGO-UWVGGRQHSA-N 0.000 description 1
- PBLLTSKBTAHDNA-KBPBESRZSA-N Lys-Gly-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O PBLLTSKBTAHDNA-KBPBESRZSA-N 0.000 description 1
- FHIAJWBDZVHLAH-YUMQZZPRSA-N Lys-Gly-Ser Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O FHIAJWBDZVHLAH-YUMQZZPRSA-N 0.000 description 1
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 1
- PDIDTSZKKFEDMB-UWVGGRQHSA-N Lys-Pro-Gly Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O PDIDTSZKKFEDMB-UWVGGRQHSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- MMJJFXWMCMJMQA-STQMWFEESA-N Phe-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CC=CC=C1 MMJJFXWMCMJMQA-STQMWFEESA-N 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- JMVQDLDPDBXAAX-YUMQZZPRSA-N Pro-Gly-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H]1CCCN1 JMVQDLDPDBXAAX-YUMQZZPRSA-N 0.000 description 1
- ABSSTGUCBCDKMU-UWVGGRQHSA-N Pro-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H]1CCCN1 ABSSTGUCBCDKMU-UWVGGRQHSA-N 0.000 description 1
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- OWCVUSJMEBGMOK-YUMQZZPRSA-N Ser-Lys-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O OWCVUSJMEBGMOK-YUMQZZPRSA-N 0.000 description 1
- RHAPJNVNWDBFQI-BQBZGAKWSA-N Ser-Pro-Gly Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O RHAPJNVNWDBFQI-BQBZGAKWSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- AVFGBGGRZOKSFS-KJEVXHAQSA-N Tyr-Met-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O AVFGBGGRZOKSFS-KJEVXHAQSA-N 0.000 description 1
- DNOOLPROHJWCSQ-RCWTZXSCSA-N Val-Arg-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DNOOLPROHJWCSQ-RCWTZXSCSA-N 0.000 description 1
- XEYUMGGWQCIWAR-XVKPBYJWSA-N Val-Gln-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N XEYUMGGWQCIWAR-XVKPBYJWSA-N 0.000 description 1
- YTPLVNUZZOBFFC-SCZZXKLOSA-N Val-Gly-Pro Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N1CCC[C@@H]1C(O)=O YTPLVNUZZOBFFC-SCZZXKLOSA-N 0.000 description 1
- XXROXFHCMVXETG-UWVGGRQHSA-N Val-Gly-Val Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O XXROXFHCMVXETG-UWVGGRQHSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010053725 prolylvaline Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000011218 seed culture Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Medicinal Chemistry (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种类I型胶原蛋白纤维的制备方法，属于基因工程技术领域。本发明以N和C端(GPP)n序列为基础，在中间插入连续的Gly‑Xaa‑Yaa三联体的胶原蛋白序列，形成三段式的嵌合胶原蛋白P‑CL‑P模式。通过N和C端的(GPP)n三股螺旋间的相互作用驱动自组装，形成具有周期性明暗相间条纹的带状纤维。本发明的方法可制备得到清洁来源的能自组装形成具有周期性明暗相间条纹的纤维，其结构与I型胶原蛋白类似，制备工艺简单，能够大规模生产成本低的胶原蛋白纤维，在生物材料领域有着广阔的应用前景。
Description
技术领域
本发明涉及一种类I型胶原蛋白纤维的制备方法，属于基因工程技术领域。
背景技术
胶原蛋白是一种生物性的高分子，是由三条链相互缠绕形成的三股螺旋结构。胶原蛋白根据其基因序列和功能作用可分为28种类型，其中最为主要是的I型胶原蛋白。在高等生物细胞中，I型胶原的原蛋白经过翻译后修饰、折叠、切割等一系列成熟化过程后，多个胶原蛋白三股螺旋(简称胶原蛋白)交错排列，形成间距均匀的明暗条纹状的胶原蛋白纤维(图1),其形貌对于细胞的粘附与生长有关键性的作用[1]，也是促进人体组织和器官的修复和再生的生物材料。
I型胶原蛋白主要用于治疗皮肤烧伤的创面敷贴、外科和牙科手术的止血海绵、骨缺损填充物等生物医用材料中，也广泛应用于化妆品与食品工业中，市场需求量庞大。目前市场上的I型胶原蛋白产品主要是来源于动物皮肤与跟腱等结缔组织，其主要优点是生物兼容性高、易被人体吸收，但是易被动物源带有的疾病如朊蛋白等污染。为了提高胶原材料的生物安全性，如何制备清洁来源的I型胶原蛋白是生物医学材料领域中备受关注的问题。
目前主要有以下三种制备方法：(1)化学合成胶原样多肽，(2)原核与真核微生物宿主异源表达重组胶原蛋白，(3)高等生物宿主异源表达，如转基因植物培育、动物细胞培养。化学合成的胶原样多肽虽然具有纯度高、易于修饰功能基团等优点，但是制备成本过高，不利于大规模生产。转基因植物和哺乳动物细胞表达体系的普遍问题是培养条件严苛、表达量低、生产周期长。微生物表达体系具有成本低和表达量高等明显优势。目前研究表明，越来越多的哺乳动物和细菌胶原被证实能够在细菌和酵母等宿主中高效的异源表达，并且正确折叠成胶原蛋白三股螺旋。重组胶原在生物材料生产中具有潜在的应用，但是缺乏形成高级结构的自组装驱动力，不能形成胶原蛋白纤维，限制了其在生物材料和组织工程方面的应用。Barbara Brodsky等人通过表达全长和两倍长度的酿脓链球菌胶原蛋白Scl2，切除球状引导折叠域后的胶原区域能够自组装形成纤维，通过加长序列长度能够促进自组装的能力，但是这些重组胶原序列无法形成与天然胶原类似的、具有规整明暗条带的纳米纤维形貌[2]。
参考文献：
1.Friedrichs,J.,A.Taubenberger,C.M.Franz,and D.J.Muller,CellularRemodelling of Individual Collagen Fibrils Visualized by Time-lapseAFM.Journal of Molecular Biology,2007.372(3):p.594-607.
2.Nelson,D.L.,A.L.Lehninger,and M.M.Cox,Lehninger principles ofbiochemistry.2008:Macmillan.
发明内容
本申请通过在不同来源的胶原蛋白的N端和C端融合表达(GPP)10，促进胶原蛋白的高聚自组装，形成胶原蛋白纤维。
本发明的第一个目的是提供一种类I型胶原蛋白，由三条蛋白单链围绕一个共同的中心轴盘绕，构成三螺旋结构；所述蛋白单链的氨基酸排布方式为：
其中，(GPP)n的n满足5＜n≤30，CL-domain的氨基酸序列如SEQID NO.2～6任一序列所示。
本发明的第二个目的是提供一种用于表达类I型胶原蛋白的蛋白单链，其氨基酸序列如
所示；其中，V-domain的氨基酸序列如SEQID NO.1所示；(GPP)n中的n≥5；CL-domain的氨基酸序列如SEQ ID NO.2～6任一序列所示。
在一种实施方式中，所述V-domain和(GPP)n之间通过LVPRGSP连接。
在一种实施方式中，(GPP)n中的n满足5＜n≤30。
在一种实施方式中，所述V-domain前端还融合6×His标签。
本发明的第三个目的是提供编码所述蛋白单链的基因。
在一种实施方式中，所述基因含有SEQ ID NO.13～18任一所示的核苷酸序列。
本发明的第三个目的是提供携带所述基因的质粒或细胞。
在一种实施方式中，所述质粒包括但不限于：pColdIII系列和pET系列质粒。
在一种实施方式中，所述质粒为pColdIII。
在一种实施方式中，所述细胞为大肠杆菌细胞，包括但不限于E.coli BL21、E.coli BL21(DE3)、E.coli JM109、E.coli DH5α或E.coli TOP10。
本发明的第五个目的是保护含有所述类I型胶原蛋白的胶原蛋白纤维；所述胶原蛋白纤维具有明暗相间的条纹形态。
在一种实施方式中，所述胶原蛋白纤维是由所述胶原蛋白高聚自组装形成。
本发明的第六个目的是提供一种类I型胶原蛋白纤维的制备方法，所述方法包括如下步骤：
(1)合成编码类I型胶原蛋白单链的基因；
(2)将步骤(1)合成的基因与载体连接，转化至目的细胞中表达并纯化；
(3)向步骤(2)的纯化产物中加入胰蛋白酶，25℃温度下反应至少6h；
(4)将步骤(3)获得的胶原蛋白配制成浓度为0.1～1mmol/L的溶液，于2℃～37℃静置。
在一种实施方式中，所述静置时间不少于24h。
在一种实施方式中，所述基因的核苷酸序列如SEQ ID NO.13～18所示。
在一种实施方式中，所述制备方法包括如下步骤：
(1)胶原蛋白重组质粒的构建：合成分别如SEQ ID NO.13～18所示的编码胶原蛋白的基因v-P10AP10,v-P10BP10,v-P10CP10,v-P10B2P10,v P10ABCP10和v-P10HP10，并分别构建到质粒pColdIII-Tu上；所述pColdIII-Tu是以pCOLD-TU(Nco I)-S:CTCGAGGGATCCGAATTCA(SEQ ID NO.23所示),pCOLD-TU(Nco I)-A:GAGCTCCATGGGCACTTTG(SEQ ID NO.24所示)为引物，对pColdIII质粒进行突变，以引入Nco I位点；
(2)转化：将重组质粒分别转化到E.coli BL21(DE3)中。
(3)诱导表达：接单菌落于LB液体培养基过夜培养，然后按1％的接种量转接TB液体培养基，37℃培养24h，加入IPTG，25℃诱导10h，转15℃诱导14h。
(4)纯化：收集发酵菌体。用磷酸盐缓冲液重悬菌体，在冰浴条件下，利用超声波细胞破碎仪破碎细胞，然后在4℃下，10000rpm离心20min去除细胞碎片，再将上清用微孔滤膜过滤去除杂质；将样品注入安装于蛋白纯化仪的His-trap hp亲和层析柱(5mL)中，然后用洗涤液冲洗8个柱体积，洗脱缓冲液中咪唑的含量呈阶梯状(140mM,400mM)增加，用来洗脱蛋白质，收集出峰蛋白，经胰蛋白酶酶切后透析后，冻干。
(5)将步骤(4)冻干后的胶原蛋白配制成浓度为0.5mmol/L的溶液，于4℃～37℃静置至少2天。
本发明还要求保护所述胶原蛋白、基因、质粒、细胞或制备方法在生物、化工、食品、医药、生物材料、组织工程和化妆品等领域中的应用。
在一种实施方式中，所述应用是用于制备含有胶原蛋白的产品，包括但不限于制备食品、药物、生物医学材料、化妆品等。
有益效果：本发明以N和C端(GPP)10序列为基础，在中间插入连续的Gly-Xaa-Yaa三联体的胶原蛋白序列，形成三段式的嵌合胶原蛋白P-CL-P模式。通过N和C端的(GPP)10三股螺旋间的相互作用驱动自组装，形成具有周期性明暗相间条纹的带状纤维。通过调整胶原区域的序列长度以精确控制纤维的明暗条纹的周期长度，并且其胶原区域序列可置换。用大肠杆菌冷休克表达本发明中涉及的胶原蛋白序列，制备得到清洁来源的能自组装形成具有周期性明暗相间条纹的纤维，其结构与I型胶原蛋白类似，制备工艺简单，能够大规模生产成本低的胶原蛋白纤维。本发明为制备类I型胶原蛋白纤维提供了制备方法及其序列设计模式，该序列的胶原区可置换、可扩展，为基于明暗条纹周期型胶原纤维的研究和应用提供了平台，在生物材料应用上有着广阔的前景。
附图说明
图1为I型胶原蛋白纤维形貌；
图2为序列设计示意图及胶原蛋白SDS-PAGE鉴定；A为三段式嵌合序列模式图,x为序列A，B，C或H；B为纯化酶切后胶原蛋白SDS-PAGE；
图3为所设计胶原蛋白MALDI-TOF分子量鉴定；A～H为MALDI-TOF分子量鉴定。
图4为所设计胶原蛋白的二级结构测定；A为圆二色谱全波长扫描谱；B为圆二色谱热变曲线。
图5为置换胶原区域序列对自组装纤维形貌的影响；A～C为P10AP10自组装纤维透射电镜图及明暗条纹长度统计；D～F为P10BP10自组装纤维透射电镜图及明暗条纹长度统计；G～I为P10CP10自组装纤维透射电镜图及明暗条纹长度统计；J～L为P10HP10自组装纤维透射电镜图及明暗条纹长度统计。
图6为改变胶原区域长度对自组装纤维形貌的影响；A～C为P10BP10自组装纤维透射电镜图及明暗条纹长度统计；D～F为P10B2P10自组装纤维透射电镜图及明暗条纹长度统计；G～I为P10ABCP10自组装纤维透射电镜图及明暗条纹长度统计。
图7为改变GPP长度对自组装纤维形貌的影响；A为P5BP5和P5B2P5圆二色谱全波长扫描谱和热变曲线；B为P5BP5和P5B2P5自组装纤维透射电镜图。
图8为P10CLP10的细胞毒性试验结果；A为不同胶原蛋白浓度下平滑肌细胞的粘附能力；B为胶原蛋白浓度为0.02mg/mL时，肌肉细胞的粘附图；C为小鼠3T3成纤细胞在胶原基底生长的细胞数量相对百分比；D为小鼠3T3成纤细胞在胶原基底生长后的荧光染色图。
图9为A为圆二色谱全波长扫描谱；B为圆二色谱热变曲线；C～F分别是CL-domain为B、P10B、BP10和BP10B的胶原蛋白透射电镜图。
具体实施方式
1、技术术语：
在不做特别说明的情况下，本申请中的“类I型胶原蛋白”是指由三条具有周期性重复(Gly-Xaa-Yaa)n的蛋白单链围绕一个共同的中心轴盘绕而成的三螺旋结构。“类I型胶原蛋白纤维”是指由类I型胶原蛋白交错排列，自发地聚集或组装形成的间距均匀并具有明暗条纹状形貌的生物大分子。
2、本发明中所用到的材料和方法：
1)培养基：
LB固体培养基：15g/L琼脂，10g/L胰蛋白胨，5g/L酵母提取粉，10g/L NaCl，pH7.0。
LB液体培养基：10g/L胰蛋白胨，5g/L酵母提取粉，10g/L NaCl，pH 7.0。
TB液体培养基：12g/L胰蛋白胨，24g酵母提取粉，甘油4mL，2.31g KH2PO4，12.54gK2HPO4，pH 7.5，定容到1L。
2)细菌培养方法：
E.coli种子培养条件：将平板划线长出的单菌落接到LB液体培养基中，培养基装液量为10％，采用250mL摇瓶进行培养，培养温度为37℃，培养时间为10h，转速为200rpm。
pET28a重组菌株发酵培养条件：采用TB培养基，培养基装液量为20％，接种量为1％，采用500mL摇瓶进行培养，培养温度为25℃，OD600达到时2.5时，采用终浓度为1mM的IPTG诱导，诱导温度为35℃，诱导时间为24h，转速为200rpm。
pCold重组菌株发酵培养条件：采用TB培养基，培养基装液量为20％，接种量为1％，采用500mL摇瓶进行培养，37℃培养24h后，采用终浓度为1mM的IPTG诱导，25℃诱导10h，然后转入15℃诱导14h，转速为200rpm。
实施例1 序列设计及胶原蛋白制备
按照
所示结构进行设计，具体步骤为：
(1)以N和C端的(GPP)10为固定的序列基元，在中间插入可变的胶原区域，得到三段式嵌合序列
(简写为P10CLP10)。本实施例中CL-domain采用来源于酿脓链球菌的胶原蛋白Scl2(Genbank ID:AAL50184.1)或来源于人源I型胶原α1链(UniProt ID:P02452.5)截取的氨基酸序列(简写为H)作为细菌胶原，其中，Scl2胶原区域分为三个等长的区域A、B和C，在以下实施例中，所设计的CL域分别为A、B、C、BB(重复的2个B区域)和ABC(相当于完整的Scl2胶原区域)。
(2)在序列N端插入来源于Scl2的球状结构域(SEQ ID NO.1所示)用于引导胶原三股螺旋正确折叠，在球状结构域和胶原区域的固定序列单元中间插入蛋白酶切位点LVPRGSP，在序列的N端插入6×His用于纯化。
氨基酸序列设计如下：
V-P10AP10(如SEQ ID NO.7所示)：
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPGQDGRNGERGEQGPTGPTGPAGPRGLQGLQGFPGERGEQGPTGPAGPRGLQGERGEQGPTGLAGKAGEAGAKGETGPAGPQGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPG；
V-P10BP10(如SEQ ID NO.8所示)：
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPRGEQGPQGLPGKDGEAGAQGPAGPMGPAGFPGERGEKGEPGTQGAKGDRGETGPVGPRGERGEAGPAGKDGERGPVGPAGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPG；
V-P10CP10(如SEQ ID NO.9所示)：
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPGKDGQNGQDGLPGKDGKDGQNGKDGLPGKDGKDGQNGKDGLPGKDGKDGQDGKDGLPGKDGKDGLPGKDGKDGQPGKPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPG；
V-P10B2P10(如SEQ ID NO.10所示)：
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPRGEQGPQGLPGKDGEAGAQGPAGPMGPAGFPGERGEKGEPGTQGAKGDRGETGPVGPRGERGEAGPAGKDGERGPVGPAGPRGEQGPQGLPGKDGEAGAQGPAGPMGPAGFPGERGEKGEPGTQGAKGDRGETGPVGPRGERGEAGPAGKDGERGPVGPAGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPG；
V-P10ABCP10(如SEQ ID NO.11所示)：
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPGQDGRNGERGEQGPTGPTGPAGPRGLQGLQGLQGERGEQGPTGPAGPRGLQGERGEQGPTGLAGKAGEAGAKGETGPAGPQGPRGEQGPQGLPGKDGEAGAQGPAGPMGPAGERGEKGEPGTQGAKGDRGETGPVGPRGERGEAGPAGKDGERGPVGPAGKDGQNGQDGLPGKDGKDGQNGKDGLPGKDGKDGQNGKDGLPGKDGKDGQDGKDGLPGKDGKDGLPGKDGKDGQPGKPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPG；
V-P10HP10(如SEQ ID NO.12所示)
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPGERGPPGPQGARGLPGAPGQMGPRGLPGERGRPGAPGPAGARGEPGAPGSKGDTGAKGEPGPVGVQGPPGPAGEEGKRGARGEPGPTGPAGPKGSPGEAGRPGEAGLPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPG；
合成编码上述氨基酸序列的基因，其中，编码V-P10AP10的核苷酸序列如SEQ IDNO.13所示；编码V-P10BP10的基因序列如SEQ ID NO.14所示；编码V-P10CP10的基因序列如SEQID NO.15所示；编码V-P10B2P10的基因序列如SEQ ID NO.16所示；编码V-P10ABCP10的基因序列如SEQ ID NO.17所示；编码V-P10HP10的核苷酸序列如SEQ ID NO.18；所示以上核苷酸序列分别包含5'NcoI酶切位点、5'侧翼序列GC和3'BamHI酶切位点。将合成的上述基因分别插入到pET28a和pCOLD III-Tu质粒的NcoI和BamHI之间，得到相应的重组胶原蛋白质粒，然后通过CaCl2法分别将重组质粒转化到E.coli BL21(DE3)感受态细胞中，涂布含有抗生素的LB平板，培养、筛选，获得制备杂合胶原蛋白的重组菌株；所述pCOLD III-Tu质粒是以SEQID NO.23和SEQ ID NO.24所示的引物，对pColdIII质粒进行突变，以引入Nco I位点。
将重组菌株诱导发酵后，将发酵液8000rpm离心5min，收集发酵菌体。用磷酸盐缓冲液重悬菌体，在冰浴条件下，利用超声波细胞破碎仪破碎细胞，然后在4℃下，10000rpm离心20min去除细胞碎片，再将上清采用微孔滤膜(0.45μm)过滤去除杂质。将样品注入安装于蛋白纯化仪上的5mL His-trap hp亲和层析柱中，然后用洗涤液冲洗8个柱体积，洗脱缓冲液中咪唑的含量呈阶梯状(140mM,400mM)增加，用来洗脱蛋白质，收集出峰蛋白，将其进行SDS-PAGE电泳分析。然后利用终浓度为0.05mg/mL胰蛋白酶在25℃下酶切6h切除球状引导折叠域，接着用Desalting脱盐柱脱盐，冷冻干燥，获得胶原蛋白冻干粉末。
取少量冻干粉末溶于水，采用SDS-PAGE和Maldi-tof鉴定。图2(B)显示酶切后的蛋白利用SDS-PAGE均检测到单一的条带，由于胶原蛋白为棒状蛋白，所用蛋白Marker为球状分子，其SDS-PAGE所示分子量大于预想分子量位置。如图3(A)～(H)所示，质谱所得分子量与理论分子量相符，得到分子量正确的胶原蛋白。
实施例2 胶原蛋白的二级结构测定
将实施例1制备获得的胶原蛋白配成1mg/mL的浓度。然后4℃静置24h以上，用1mm的比色皿，在4℃下进行圆二色谱全波长扫描，波长从190nm到260nm，波长间隔1nm，每个波长下停留5s。热变实验在220nm下测定，温度从4℃到80℃，每个温度平衡8s，温度递增速度为1℃/6min。典型的胶原蛋白三股螺旋结构CD谱图显示为220nm的正吸收峰。
如图4所示，全波长扫描下，实施例1所设计蛋白在220nm附近都有特征吸收峰；热变实验结果显示，随着温度的升高，220nm下的特征吸收值在50℃左右都骤变，表现为胶原蛋白二级结构的破坏，及三股螺旋解螺旋。CD全谱和热变试验结果都说明实施例1所设计的三段式嵌合胶原蛋白都能够正确折叠形成胶原三股螺旋结构，并且有很高的热稳定型。
实施例3 置换胶原区域序列对纤维结构的影响
将实施例1制备的冻干的胶原蛋白P10AP10,P10BP10,P10CP10，P10HP10用10mM PB配成终浓度为0.5mM的溶液，4℃下放置3.5天数后取少量滴在铜网上，吸附45s后用滤纸吸干，然后用0.75％的磷钨酸负染20s，滤纸吸干，用Hitachi H-7650透射电子显微镜观察，如图5所示的透射电镜结果，所设计的胶原蛋白均能够自组装形成具有周期性明暗相间条纹的带状纤维，序列A、B和C形成的周期性明暗条纹长度一致。通过对负染的P10BP10纤维明纹和暗纹进行测量，对至少5张不同的TEM图片，200组以上数据统计得到明纹和暗纹长度分别为10.4nm和24.0nm，与(PPG)10和A,B,C序列的理论长度相符，每个Gly-Xaa-Yaa三联体的长度为0.9nm左右，序列A，B和C的长度都为81个氨基酸，即27个三联体，理论长度为24.3nm，来源于人源序列也能在该模式下自组装形成明暗条纹纤维，其明纹与理论(PPG)10长度相符，暗纹长度为32.6nm，与序列H(36个Gly-Xaa-Yaa三联体)理论长度相符，证明该三段式嵌合的设计模式在N和C端(PPG)10的驱动下能形成稳定的周期型纤维且不受胶原区域序列置换的影响。
实施例4 通过胶原区域长度控制纤维的周期长度
将冻干的胶原蛋白P10BP10,P10B2P10,P10ABCP10按照实施例3的方法观察其纤维形貌，透射电镜结果显示如图6，纤维的暗条纹随着序列长度的变化而变化，依次为24.0nm、47.4nm、和72.3nm，与胶原区域B、2B和ABC的理论长度相符合,P10B2P10的暗条纹约为P10BP10的2倍，P10ABCP10的暗条纹约为P10BP10的3倍，明纹长度均为10nm左右，试验结果表明在该三段式嵌合序列模式下，能通过调节胶原区域长度控制胶原纤维暗条纹的长度。
实施例5 胶原蛋白纤维的功能验证
将实施例3中自组装后的纤维稀释至浓度为0.02、0.04、0.08和0.1mg/mL。然后将胶原蛋白纤维溶液和作为阴性对照的5％牛血清蛋白(BSA)，以及作为阳性对照的0.04mg/mL的I型胶原蛋白分别取200μL加入48孔板中，每组三个平行，于4℃下吸附24h。然后吸出溶液，加入200μL DMEM培养基(含5％BSA)室温放置2h。接着PBS缓冲液清洗3次，然后将肌肉细胞以每孔20000个细胞的密度重悬于含有10％FBS的DMEM，接种200μL到细胞培养板上，2h后，吸出细胞悬浮液，用PBS清洗3次，然后用水晶紫染色测量590nm下的吸收并观察细胞粘附情况。
如图8(A)和(B)所示，P10BP10和P10B2P10相比于BSA，能够很好的促进细胞的粘附，不同浓度下其对细胞的粘附能力没有很大的影响，在0.04mg/mL浓度下，其粘附能力分别约为天然I型胶原的0.58倍和0.57倍。
以同样的方式将胶原纤维吸附到96孔板上，然后将小鼠3T3细胞以每孔5000个细胞的密度重悬于含有4％FBS的DMEM，接种100μL到细胞培养板上，培养24h后，利用Dapi和鬼笔环肽染色，统计细胞数量并观察细胞形貌。如图8(C)和(D)所示，P10BP10和P10B2P10对3T3细胞的粘附能力能媲美于天然I型胶原，为I型胶原的0.94倍和1.31倍，观察其细胞形貌可知，以P10BP10和P10B2P10为基底的3T3细胞生长状况良好，细胞伸展度较高。
按照上述方法对实施例1制备获得的其他胶原蛋白纤维的功能进行验证，结果显示，粘附能力和细胞伸展度均与P10BP10和P10B2P10效果相当。
对比例1：
具体实施方式同实施例1，区别在于，将(PPG)10替换为(PPG)5，
V-P5BP5的氨基酸序列如SEQ ID NO.19所示，编码该氨基酸序列的核苷酸序列如SEQ ID NO.20所示。
V-P5B2P5的氨基酸序列如SEQ ID NO.21所示，编码该氨基酸序列的核苷酸序列如SEQ ID NO.22所示。
如图7所示，全波长扫描和热变实验结果都说明本专利中所设计的嵌合胶原蛋白P5BP5和P5B2P5都能够正确折叠形成胶原三股螺旋结构，并且有很高的热稳定型，但透射电镜结果显示，所设计的胶原蛋白P5BP5和P5BP5虽然能够自组装形成纤维，但是不具有周期性明暗相间条纹。
对比例2
具体实施方式同实施例1，区别在于，仅在CL-domain(此处利用Scl2的B胶原区域)的C端、N端或者中间嵌接(GPP)10，或不加入(GPP)10。
(1)V-B的氨基酸序列：
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPRGEQGPQGLPGKDGEAGAQGPAGPMGPAGFPGERGEKGEPGTQGAKGDRGETGPVGPRGERGEAGPAGKDGERGPVGPAG；
编码V-B的核苷酸序列：
CCATGGGCCATCATCATCATCACCACGCCGATGAACAAGAAGAGAAAGCAAAGGTGCGCACCGAACTGATTCAAGAACTGGCACAAGGTCTGGGCGGTATCGAAAAGAAGAACTTCCCGACTTTAGGTGATGAGGATTTAGATCACACCTACATGACCAAACTGCTGACCTATTTACAAGAACGCGAACAAGCTGAAAATAGCTGGCGCAAACGTCTGCTGAAAGGCATCCAAGATCATGCACTGGATCTGGTTCCGCGTGGTAGCCCCGGTCCTCGCGGTGAACAAGGTCCGCAAGGTCTGCCGGGTAAAGATGGTGAAGCCGGTGCACAAGGTCCGGCTGGTCCTATGGGCCCGGCCGGCTTTCCGGGCGAACGTGGTGAAAAAGGCGAACCGGGTACCCAAGGTGCCAAAGGTGATCGTGGCGAAACCGGTCCGGTTGGCCCTCGTGGCGAACGCGGTGAAGCTGGTCCGGCTGGCAAAGACGGTGAACGTGGTCCCGTTGGTCCGGCCGGTTAAGGATCC；
(2)V-P10B的氨基酸序列：
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPRGEQGPQGLPGKDGEAGAQGPAGPMGPAGFPGERGEKGEPGTQGAKGDRGETGPVGPRGERGEAGPAGKDGERGPVGPAG；
编码V-P10B的核苷酸序列：
CCATGGGCCATCATCATCATCACCACGCCGATGAGCAAGAAGAAAAGGCCAAGGTTCGCACCGAACTGATTCAAGAACTGGCCCAAGGTCTGGGTGGCATCGAGAAAAAGAACTTCCCGACTTTAGGCGACGAAGATTTAGACCACACCTATATGACCAAGCTGCTGACCTATTTACAAGAACGCGAACAAGCTGAAAACAGTTGGCGTAAACGTTTACTGAAGGGTATCCAAGATCACGCACTGGATCTGGTTCCGCGTGGTTCTCCCGGTCCCCCCGGCCCCCCCGGTCCCCCCGGTCCCCCCGGTCCTCCCGGCCCCCCCGGTCCCCCCGGTCCTCCGGGTCCCCCCGGTCCGCCCGGTCCCCGTGGTGAACAAGGCCCGCAAGGTTTACCGGGCAAAGACGGTGAAGCTGGTGCACAAGGTCCGGCTGGTCCTATGGGCCCGGCCGGTTTTCCGGGTGAGCGTGGTGAAAAAGGCGAACCGGGCACACAAGGCGCAAAAGGTGATCGCGGTGAAACCGGCCCCGTTGGCCCTCGTGGCGAACGTGGCGAAGCTGGTCCGGCCGGCAAAGATGGTGAGCGTGGCCCCGTTGGCCCCGCTGGCTAAGGATCC；
(3)V-BP10的氨基酸序列：
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPRGEQGPQGLPGKDGEAGAQGPAGPMGPAGFPGERGEKGEPGTQGAKGDRGETGPVGPRGERGEAGPAGKDGERGPVGPAGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPG；
编码V-BP10的核苷酸序列：
CCATGGGCCATCATCATCATCACCACGCCGATGAGCAAGAAGAAAAGGCCAAGGTTCGCACCGAACTGATTCAAGAACTGGCCCAAGGTCTGGGTGGCATCGAGAAAAAGAACTTCCCGACTTTAGGCGACGAAGATTTAGACCACACCTATATGACCAAGCTGCTGACCTATTTACAAGAACGCGAACAAGCTGAAAACAGTTGGCGTAAACGTTTACTGAAGGGTATCCAAGATCACGCACTGGATCTGGTTCCGCGTGGTTCTCCCGGTCCGCGTGGCGAACAAGGTCCTCAAGGTTTACCGGGTAAAGATGGCGAAGCCGGTGCACAAGGTCCCGCTGGTCCTATGGGTCCCGCTGGTTTTCCCGGTGAACGCGGCGAAAAAGGTGAACCCGGTACCCAAGGTGCAAAGGGTGACCGTGGTGAGACCGGTCCCGTTGGCCCTCGTGGTGAACGTGGTGAAGCCGGTCCGGCTGGTAAAGACGGCGAGCGCGGCCCGGTTGGCCCCGCTGGCCCCCCCGGTCCCCCCGGTCCCCCCGGTCCTCCCGGTCCCCCCGGTCCGCCCGGTCCCCCCGGTCCCCCCGGTCCCCCCGGTCCTCCGGGCTAAGGATCC；
(4)V-BP10B的氨基酸序列：
HHHHHHADEQEEKAKVRTELIQELAQGLGGIEKKNFPTLGDEDLDHTYMTKLLTYLQEREQAENSWRKRLLKGIQDHALDLVPRGSPGPRGEQGPQGLPGKDGEAGAQGPAGPMGPAGFPGERGEKGEPGPPGPPGPPGPPGPPGPPGPPGPPGPPGPPGTQGAKGDRGETGPVGPRGERGEAGPAGKDGERGPVGPAG；
编码V-BP10B的核苷酸序列：
CCATGGGCCATCATCACCATCACCATGCCGATGAGCAAGAAGAAAAAGCCAAAGTGCGCACCGAACTGATCCAAGAACTGGCACAAGGTCTGGGTGGCATCGAGAAGAAAAACTTCCCGACTTTAGGCGATGAAGATTTAGACCACACCTACATGACCAAACTGCTGACCTATTTACAAGAACGTGAGCAAGCTGAGAATAGCTGGCGCAAGCGTTTACTGAAAGGCATTCAAGATCATGCTTTAGATTTAGTTCCGCGTGGTAGTCCGGGTCCGCGTGGTGAACAAGGTCCTCAAGGTCTGCCGGGTAAAGACGGTGAAGCTGGTGCCCAAGGCCCGGCTGGTCCGATGGGTCCCGCTGGTTTTCCGGGCGAACGTGGTGAAAAAGGTGAACCCGGTCCCCCGGGTCCTCCCGGTCCGCCGGGCCCGCCCGGTCCCCCCGGTCCGCCCGGTCCCCCGGGCCCCCCCGGTCCTCCCGGCCCTCCGGGTACCCAAGGTGCCAAAGGTGATCGTGGTGAAACTGGTCCGGTTGGTCCTCGCGGTGAACGCGGCGAAGCTGGTCCCGCTGGTAAAGATGGTGAGCGCGGTCCCGTTGGTCCGGCTGGTTAAGGATCC；
如图8所示，结果显示都能够正确折叠形成胶原三股螺旋结构，但是透射电镜结果显示，所设计的胶原蛋白均不能够能够自组装形成纤维。
虽然本发明已以较佳实施例公开如上，但其并非用以限定本发明，任何熟悉此技术的人，在不脱离本发明的精神和范围内，都可做各种的改动与修饰，因此本发明的保护范围应该以权利要求书所界定的为准。
SEQUENCE LISTING
<110> 江南大学
罗格斯大学
<120> 一种类I型胶原蛋白纤维的制备方法
<160> 24
<170> PatentIn version 3.3
<210> 1
<211> 74
<212> PRT
<213> 人工序列
<400> 1
Ala Asp Glu Gln Glu Glu Lys Ala Lys Val Arg Thr Glu Leu Ile Gln
1 5 10 15
Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu Lys Lys Asn Phe Pro Thr
20 25 30
Leu Gly Asp Glu Asp Leu Asp His Thr Tyr Met Thr Lys Leu Leu Thr
35 40 45
Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn Ser Trp Arg Lys Arg Leu
50 55 60
Leu Lys Gly Ile Gln Asp His Ala Leu Asp
65 70
<210> 2
<211> 81
<212> PRT
<213> Streptococcus pyogenes
<400> 2
Gln Asp Gly Arg Asn Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly Pro
1 5 10 15
Thr Gly Pro Ala Gly Pro Arg Gly Leu Gln Gly Leu Gln Gly Phe Pro
20 25 30
Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly Pro Ala Gly Pro Arg Gly
35 40 45
Leu Gln Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly Leu Ala Gly Lys
50 55 60
Ala Gly Glu Ala Gly Ala Lys Gly Glu Thr Gly Pro Ala Gly Pro Gln
65 70 75 80
Gly
<210> 3
<211> 81
<212> PRT
<213> Streptococcus pyogenes
<400> 3
Pro Arg Gly Glu Gln Gly Pro Gln Gly Leu Pro Gly Lys Asp Gly Glu
1 5 10 15
Ala Gly Ala Gln Gly Pro Ala Gly Pro Met Gly Pro Ala Gly Phe Pro
20 25 30
Gly Glu Arg Gly Glu Lys Gly Glu Pro Gly Thr Gln Gly Ala Lys Gly
35 40 45
Asp Arg Gly Glu Thr Gly Pro Val Gly Pro Arg Gly Glu Arg Gly Glu
50 55 60
Ala Gly Pro Ala Gly Lys Asp Gly Glu Arg Gly Pro Val Gly Pro Ala
65 70 75 80
Gly
<210> 4
<211> 78
<212> PRT
<213> Streptococcus pyogenes
<400> 4
Lys Asp Gly Gln Asn Gly Gln Asp Gly Leu Pro Gly Lys Asp Gly Lys
1 5 10 15
Asp Gly Gln Asn Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp
20 25 30
Gly Gln Asn Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp Gly
35 40 45
Gln Asp Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp Gly Leu
50 55 60
Pro Gly Lys Asp Gly Lys Asp Gly Gln Pro Gly Lys Pro Gly
65 70 75
<210> 5
<211> 237
<212> PRT
<213> Streptococcus pyogenes
<400> 5
Gln Asp Gly Arg Asn Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly Pro
1 5 10 15
Thr Gly Pro Ala Gly Pro Arg Gly Leu Gln Gly Leu Gln Gly Leu Gln
20 25 30
Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly Pro Ala Gly Pro Arg Gly
35 40 45
Leu Gln Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly Leu Ala Gly Lys
50 55 60
Ala Gly Glu Ala Gly Ala Lys Gly Glu Thr Gly Pro Ala Gly Pro Gln
65 70 75 80
Gly Pro Arg Gly Glu Gln Gly Pro Gln Gly Leu Pro Gly Lys Asp Gly
85 90 95
Glu Ala Gly Ala Gln Gly Pro Ala Gly Pro Met Gly Pro Ala Gly Glu
100 105 110
Arg Gly Glu Lys Gly Glu Pro Gly Thr Gln Gly Ala Lys Gly Asp Arg
115 120 125
Gly Glu Thr Gly Pro Val Gly Pro Arg Gly Glu Arg Gly Glu Ala Gly
130 135 140
Pro Ala Gly Lys Asp Gly Glu Arg Gly Pro Val Gly Pro Ala Gly Lys
145 150 155 160
Asp Gly Gln Asn Gly Gln Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp
165 170 175
Gly Gln Asn Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp Gly
180 185 190
Gln Asn Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp Gly Gln
195 200 205
Asp Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp Gly Leu Pro
210 215 220
Gly Lys Asp Gly Lys Asp Gly Gln Pro Gly Lys Pro Gly
225 230 235
<210> 6
<211> 108
<212> PRT
<213> Homo sapiens
<400> 6
Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala Arg Gly Leu Pro Gly
1 5 10 15
Ala Pro Gly Gln Met Gly Pro Arg Gly Leu Pro Gly Glu Arg Gly Arg
20 25 30
Pro Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly Glu Pro Gly Ala Pro
35 40 45
Gly Ser Lys Gly Asp Thr Gly Ala Lys Gly Glu Pro Gly Pro Val Gly
50 55 60
Val Gln Gly Pro Pro Gly Pro Ala Gly Glu Glu Gly Lys Arg Gly Ala
65 70 75 80
Arg Gly Glu Pro Gly Pro Thr Gly Pro Ala Gly Pro Lys Gly Ser Pro
85 90 95
Gly Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu Pro
100 105
<210> 7
<211> 229
<212> PRT
<213> 人工序列
<400> 7
His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys Val
1 5 10 15
Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu
20 25 30
Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr Tyr
35 40 45
Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn
50 55 60
Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu Asp
65 70 75 80
Leu Val Pro Arg Gly Ser Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
85 90 95
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
100 105 110
Pro Pro Gly Pro Pro Gly Gln Asp Gly Arg Asn Gly Glu Arg Gly Glu
115 120 125
Gln Gly Pro Thr Gly Pro Thr Gly Pro Ala Gly Pro Arg Gly Leu Gln
130 135 140
Gly Leu Gln Gly Phe Pro Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly
145 150 155 160
Pro Ala Gly Pro Arg Gly Leu Gln Gly Glu Arg Gly Glu Gln Gly Pro
165 170 175
Thr Gly Leu Ala Gly Lys Ala Gly Glu Ala Gly Ala Lys Gly Glu Thr
180 185 190
Gly Pro Ala Gly Pro Gln Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
195 200 205
Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
210 215 220
Pro Gly Pro Pro Gly
225
<210> 8
<211> 229
<212> PRT
<213> 人工序列
<400> 8
His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys Val
1 5 10 15
Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu
20 25 30
Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr Tyr
35 40 45
Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn
50 55 60
Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu Asp
65 70 75 80
Leu Val Pro Arg Gly Ser Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
85 90 95
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
100 105 110
Pro Pro Gly Pro Pro Gly Pro Arg Gly Glu Gln Gly Pro Gln Gly Leu
115 120 125
Pro Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Ala Gly Pro Met
130 135 140
Gly Pro Ala Gly Phe Pro Gly Glu Arg Gly Glu Lys Gly Glu Pro Gly
145 150 155 160
Thr Gln Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly Pro Val Gly Pro
165 170 175
Arg Gly Glu Arg Gly Glu Ala Gly Pro Ala Gly Lys Asp Gly Glu Arg
180 185 190
Gly Pro Val Gly Pro Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
195 200 205
Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
210 215 220
Pro Gly Pro Pro Gly
225
<210> 9
<211> 226
<212> PRT
<213> 人工序列
<400> 9
His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys Val
1 5 10 15
Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu
20 25 30
Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr Tyr
35 40 45
Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn
50 55 60
Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu Asp
65 70 75 80
Leu Val Pro Arg Gly Ser Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
85 90 95
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
100 105 110
Pro Pro Gly Pro Pro Gly Lys Asp Gly Gln Asn Gly Gln Asp Gly Leu
115 120 125
Pro Gly Lys Asp Gly Lys Asp Gly Gln Asn Gly Lys Asp Gly Leu Pro
130 135 140
Gly Lys Asp Gly Lys Asp Gly Gln Asn Gly Lys Asp Gly Leu Pro Gly
145 150 155 160
Lys Asp Gly Lys Asp Gly Gln Asp Gly Lys Asp Gly Leu Pro Gly Lys
165 170 175
Asp Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp Gly Gln Pro
180 185 190
Gly Lys Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
195 200 205
Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
210 215 220
Pro Gly
225
<210> 10
<211> 310
<212> PRT
<213> 人工序列
<400> 10
His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys Val
1 5 10 15
Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu
20 25 30
Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr Tyr
35 40 45
Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn
50 55 60
Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu Asp
65 70 75 80
Leu Val Pro Arg Gly Ser Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
85 90 95
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
100 105 110
Pro Pro Gly Pro Pro Gly Pro Arg Gly Glu Gln Gly Pro Gln Gly Leu
115 120 125
Pro Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Ala Gly Pro Met
130 135 140
Gly Pro Ala Gly Phe Pro Gly Glu Arg Gly Glu Lys Gly Glu Pro Gly
145 150 155 160
Thr Gln Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly Pro Val Gly Pro
165 170 175
Arg Gly Glu Arg Gly Glu Ala Gly Pro Ala Gly Lys Asp Gly Glu Arg
180 185 190
Gly Pro Val Gly Pro Ala Gly Pro Arg Gly Glu Gln Gly Pro Gln Gly
195 200 205
Leu Pro Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Ala Gly Pro
210 215 220
Met Gly Pro Ala Gly Phe Pro Gly Glu Arg Gly Glu Lys Gly Glu Pro
225 230 235 240
Gly Thr Gln Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly Pro Val Gly
245 250 255
Pro Arg Gly Glu Arg Gly Glu Ala Gly Pro Ala Gly Lys Asp Gly Glu
260 265 270
Arg Gly Pro Val Gly Pro Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro
275 280 285
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
290 295 300
Pro Pro Gly Pro Pro Gly
305 310
<210> 11
<211> 385
<212> PRT
<213> 人工序列
<400> 11
His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys Val
1 5 10 15
Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu
20 25 30
Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr Tyr
35 40 45
Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn
50 55 60
Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu Asp
65 70 75 80
Leu Val Pro Arg Gly Ser Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
85 90 95
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
100 105 110
Pro Pro Gly Pro Pro Gly Gln Asp Gly Arg Asn Gly Glu Arg Gly Glu
115 120 125
Gln Gly Pro Thr Gly Pro Thr Gly Pro Ala Gly Pro Arg Gly Leu Gln
130 135 140
Gly Leu Gln Gly Leu Gln Gly Glu Arg Gly Glu Gln Gly Pro Thr Gly
145 150 155 160
Pro Ala Gly Pro Arg Gly Leu Gln Gly Glu Arg Gly Glu Gln Gly Pro
165 170 175
Thr Gly Leu Ala Gly Lys Ala Gly Glu Ala Gly Ala Lys Gly Glu Thr
180 185 190
Gly Pro Ala Gly Pro Gln Gly Pro Arg Gly Glu Gln Gly Pro Gln Gly
195 200 205
Leu Pro Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Ala Gly Pro
210 215 220
Met Gly Pro Ala Gly Glu Arg Gly Glu Lys Gly Phe Pro Gly Glu Arg
225 230 235 240
Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly Pro Val Gly Pro Arg Gly
245 250 255
Glu Arg Gly Glu Ala Gly Pro Ala Gly Lys Asp Gly Glu Arg Gly Pro
260 265 270
Val Gly Pro Ala Gly Lys Asp Gly Gln Asn Gly Gln Asp Gly Leu Pro
275 280 285
Gly Lys Asp Gly Lys Asp Gly Gln Asn Gly Lys Asp Gly Leu Pro Gly
290 295 300
Lys Asp Gly Lys Asp Gly Gln Asn Gly Lys Asp Gly Leu Pro Gly Lys
305 310 315 320
Asp Gly Lys Asp Gly Gln Asp Gly Lys Asp Gly Leu Pro Gly Lys Asp
325 330 335
Gly Lys Asp Gly Leu Pro Gly Lys Asp Gly Lys Asp Gly Gln Pro Gly
340 345 350
Lys Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro
355 360 365
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
370 375 380
Gly
385
<210> 12
<211> 256
<212> PRT
<213> 人工序列
<400> 12
His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys Val
1 5 10 15
Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu
20 25 30
Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr Tyr
35 40 45
Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn
50 55 60
Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu Asp
65 70 75 80
Leu Val Pro Arg Gly Ser Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
85 90 95
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
100 105 110
Pro Pro Gly Pro Pro Gly Glu Arg Gly Pro Pro Gly Pro Gln Gly Ala
115 120 125
Arg Gly Leu Pro Gly Ala Pro Gly Gln Met Gly Pro Arg Gly Leu Pro
130 135 140
Gly Glu Arg Gly Arg Pro Gly Ala Pro Gly Pro Ala Gly Ala Arg Gly
145 150 155 160
Glu Pro Gly Ala Pro Gly Ser Lys Gly Asp Thr Gly Ala Lys Gly Glu
165 170 175
Pro Gly Pro Val Gly Val Gln Gly Pro Pro Gly Pro Ala Gly Glu Glu
180 185 190
Gly Lys Arg Gly Ala Arg Gly Glu Pro Gly Pro Thr Gly Pro Ala Gly
195 200 205
Pro Lys Gly Ser Pro Gly Glu Ala Gly Arg Pro Gly Glu Ala Gly Leu
210 215 220
Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
225 230 235 240
Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro Gly
245 250 255
<210> 13
<211> 704
<212> DNA
<213> 人工序列
<400> 13
ccatgggcca ccaccatcac caccacgccg atgaacaaga agaaaaggcg aaggtgcgca 60
cggaactgat tcaagaactg gcccaaggtc tgggcggcat tgagaagaag aactttccga 120
cgctgggtga cgaagacctc gatcacacct acatgaccaa gctgctgacg tatctccaag 180
aacgcgaaca agccgagaat agctggcgta aacgtctgct caaaggcatc caagatcacg 240
cgctggatct ggtgccacgt ggtagtccgg gtccaccggg cccaccgggt ccaccgggcc 300
cgccgggccc gccgggcccg ccgggcccac cgggcccgcc gggcccgccg ggcccaccgg 360
gccaagatgg tcgcaatggt gagcgtggtg aacaaggtcc gacgggtccg accggtccag 420
ccggtccgcg tggtctgcaa ggtctgcaag gcttcccggg cgaacgtggc gaacaaggcc 480
cgacgggtcc agccggccca cgtggtctgc aaggtgaacg cggcgaacaa ggtccaaccg 540
gtctggcggg taaagcgggt gaagccggtg cgaaaggtga aacgggccca gcgggtccac 600
aaggcccgcc gggcccaccg ggtccaccgg gtccaccggg cccaccgggc ccgccgggcc 660
cgccgggccc gccgggcccg ccgggcccgc cgggctaagg atcc 704
<210> 14
<211> 704
<212> DNA
<213> 人工序列
<400> 14
ccatgggcca tcaccaccat catcacgccg atgaacaaga agagaaagcc aaagtgcgca 60
ccgaactgat tcaagaactg gcccaaggtc tgggtggcat tgagaagaag aactttccga 120
cgctgggcga cgaagatctg gaccacacgt acatgaccaa gctgctgacc tatctgcaag 180
aacgcgaaca agccgaaaac agttggcgca aacgtctgct gaaaggcatc caagatcacg 240
cgctggatct cgttccacgt ggtagtccgg gtccaccggg cccaccgggt ccaccgggcc 300
caccgggccc accgggccca ccgggcccgc cgggcccgcc gggcccaccg ggcccaccgg 360
gtccacgcgg tgaacaaggc ccgcaaggtc tgccgggcaa agatggtgag gcgggtgcgc 420
aaggtccagc cggtccaatg ggtccagccg gtttcccggg cgaacgcggt gaaaaaggcg 480
aaccgggtac gcaaggcgcc aaaggtgatc gcggtgaaac gggtccagtt ggcccgcgtg 540
gtgaacgtgg tgaagcgggt ccggccggta aagacggtga acgcggccca gttggtccgg 600
ccggcccacc gggcccaccg ggcccaccgg gcccaccggg cccgccgggc ccgccgggcc 660
cgccgggtcc gccgggtcca ccgggcccac cgggctaagg atcc 704
<210> 15
<211> 695
<212> DNA
<213> 人工序列
<400> 15
ccatgggcca ccatcatcac catcacgcgg atgagcaaga agagaaagcg aaagtgcgca 60
cggagctgat ccaagaactg gcgcaaggcc tcggcggtat cgagaagaag aacttcccga 120
cgctgggtga tgaggatctg gaccacacgt acatgaccaa actgctcacc tatctgcaag 180
aacgcgaaca agccgaaaac agctggcgca agcgtctgct gaaaggcatt caagatcacg 240
ccctcgatct ggttccgcgc ggtagtccgg gcccaccggg cccgccgggc ccgccgggcc 300
caccgggccc gccgggccca ccgggtccac cgggcccgcc gggcccaccg ggcccgccgg 360
gcaaagatgg tcagaatggt caagatggtc tcccgggtaa agatggcaaa gacggtcaaa 420
acggtaaaga cggtctgccg ggcaaggatg gtaaggatgg tcagaacggc aaggacggtc 480
tgccgggcaa agatggtaaa gacggccaag atggtaagga cggtctcccg ggtaaggatg 540
gcaaagatgg tctgccgggc aaggacggca aagatggcca accgggcaaa ccgggcccac 600
cgggcccgcc gggtccaccg ggtccgccgg gcccgccggg tccaccgggc ccaccgggcc 660
cgccgggccc accgggtccg ccgggctaag gatcc 695
<210> 16
<211> 947
<212> DNA
<213> 人工序列
<400> 16
ccatgggcca tcaccaccat catcacgccg atgaacaaga agagaaagcc aaagtgcgca 60
ccgaactgat tcaagaactg gcccaaggtc tgggtggcat tgagaagaag aactttccga 120
cgctgggcga cgaagatctg gaccacacgt acatgaccaa gctgctgacc tatctgcaag 180
aacgcgaaca agccgaaaac agttggcgca aacgtctgct gaaaggcatc caagatcacg 240
cgctggatct cgttccacgt ggtagtccgg gtccaccggg cccaccgggt ccaccgggcc 300
caccgggccc accgggccca ccgggcccgc cgggcccgcc gggcccaccg ggcccaccgg 360
gtccacgcgg tgaacaaggc ccgcaaggtc tgccgggcaa agatggtgag gcgggtgcgc 420
aaggtccagc cggtccaatg ggtccagccg gtttcccggg cgaacgcggt gaaaaaggcg 480
aaccgggtac gcaaggcgcc aaaggtgatc gcggtgaaac gggtccagtt ggcccgcgtg 540
gtgaacgtgg tgaagcgggt ccggccggta aagacggtga acgcggccca gttggtccgg 600
ccggcccacg cggtgaacaa ggcccgcaag gtctgccggg caaagatggt gaggcgggtg 660
cgcaaggtcc agccggtcca atgggtccag ccggtttccc gggcgaacgc ggtgaaaaag 720
gcgaaccggg tacgcaaggc gccaaaggtg atcgcggtga aacgggtcca gttggcccgc 780
gtggtgaacg tggtgaagcg ggtccggccg gtaaagacgg tgaacgcggc ccagttggtc 840
cggccggccc accgggccca ccgggcccac cgggcccacc gggcccgccg ggcccgccgg 900
gcccgccggg tccgccgggt ccaccgggcc caccgggcta aggatcc 947
<210> 17
<211> 1172
<212> DNA
<213> 人工序列
<400> 17
ccatgggcca ccaccatcat catcacgcgg acgagcaaga agagaaagcc aaagttcgca 60
ccgagctgat tcaagaactg gcgcaaggcc tcggcggtat cgagaagaag aactttccga 120
cgctgggcga tgaggatctg gaccatacgt acatgacgaa gctgctgacc tatctgcaag 180
aacgcgaaca agcggaaaac agctggcgca agcgcctcct caaaggcatc caagatcatg 240
ccctcgatct ggttccgcgt ggtagcccgg gcccgccggg cccgccgggc ccaccgggcc 300
cgccgggccc accgggtccg ccgggtccgc cgggcccgcc gggcccaccg ggcccgccgg 360
gccaagatgg ccgtaacggc gaacgtggtg agcaaggccc aacgggcccg acgggtccgg 420
cgggtccacg tggtctccaa ggtctccaag gtctgcaagg cgaacgcggt gaacaaggtc 480
cgaccggtcc ggccggtccg cgtggcctcc aaggcgaacg cggcgaacaa ggcccaaccg 540
gtctggcggg caaagcgggc gaggcgggtg cgaaaggtga aaccggccca gcgggtccac 600
aaggtccgcg tggtgaacaa ggcccgcaag gtctgccggg caaggatggc gaagcgggcg 660
cgcaaggtcc ggccggcccg atgggtccag cgggcgagcg cggtgaaaaa ggcttcccgg 720
gcgagcgtgg cgccaaaggc gatcgcggcg aaacgggtcc agttggtcca cgcggtgaac 780
gcggcgaagc cggtccagcc ggtaaagatg gcgaacgtgg tccagttggc ccagccggta 840
aggatggtca gaatggtcaa gatggcctcc cgggcaagga cggtaaggat ggtcagaatg 900
gtaaagacgg tctgccgggc aaagatggca aggatggcca gaacggcaaa gatggtctcc 960
cgggtaagga cggcaaagac ggccaagatg gcaaagacgg cctcccgggc aaggatggca 1020
aggacggtct cccgggtaaa gacggtaagg atggtcagcc gggcaaaccg ggtccaccgg 1080
gcccgccggg tccgccgggt ccaccgggcc caccgggccc gccgggccca ccgggcccac 1140
cgggtccacc gggcccaccg ggctaaggat cc 1172
<210> 18
<211> 785
<212> DNA
<213> 人工序列
<400> 18
ccatgggcca tcatcaccat caccacgccg acgaacaaga agagaaagcc aaggttcgca 60
ccgaactgat tcaagaactg gcgcaaggtc tgggcggcat cgagaaaaaa aacttcccga 120
ccctcggcga tgaggacctc gatcacacgt acatgacgaa actgctgacg tatctgcaag 180
aacgtgaaca agccgaaaac agctggcgca aacgtctgct gaaaggcatc caagatcacg 240
cgctggatct cgtgccacgc ggtagtccgg gcccgccggg cccaccgggc ccaccgggcc 300
caccgggccc gccgggcccg ccgggtccac cgggcccacc gggtccgccg ggcccgccgg 360
gtgagcgtgg tccgccgggc ccacaaggcg cgcgcggtct gccgggcgcg ccgggccaaa 420
tgggtccacg tggtctgccg ggtgaacgtg gccgtccggg cgcgccgggc ccagcgggcg 480
cccgtggtga accgggtgcc ccgggcagca aaggcgatac gggtgccaaa ggcgaaccgg 540
gcccggttgg cgttcaaggc ccaccgggcc cagccggtga agaaggtaaa cgcggcgccc 600
gcggtgaacc gggcccaacg ggtccagcgg gcccaaaagg tagcccgggc gaagcgggtc 660
gtccgggcga agccggtctg ccgggcccgc cgggcccgcc gggtccaccg ggcccgccgg 720
gcccaccggg cccaccgggc ccgccgggcc caccgggccc accgggccca ccgggctaag 780
gatcc 785
<210> 19
<211> 199
<212> PRT
<213> 人工序列
<400> 19
His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys Val
1 5 10 15
Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu
20 25 30
Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr Tyr
35 40 45
Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn
50 55 60
Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu Asp
65 70 75 80
Leu Val Pro Arg Gly Ser Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
85 90 95
Gly Pro Pro Gly Pro Pro Gly Pro Arg Gly Glu Gln Gly Pro Gln Gly
100 105 110
Leu Pro Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Ala Gly Pro
115 120 125
Met Gly Pro Ala Gly Phe Pro Gly Glu Arg Gly Glu Lys Gly Glu Pro
130 135 140
Gly Thr Gln Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly Pro Val Gly
145 150 155 160
Pro Arg Gly Glu Arg Gly Glu Ala Gly Pro Ala Gly Lys Asp Gly Glu
165 170 175
Arg Gly Pro Val Gly Pro Ala Gly Pro Pro Gly Pro Pro Gly Pro Pro
180 185 190
Gly Pro Pro Gly Pro Pro Gly
195
<210> 20
<211> 614
<212> DNA
<213> 人工序列
<400> 20
ccatgggcca tcatcatcac catcacgcag acgaacaaga agaaaaggcc aaagtgcgca 60
ccgaactgat tcaagaatta gcccaaggtt taggtggcat cgagaagaaa aactttccga 120
ctttaggcga tgaggatctg gaccacacct acatgaccaa gctgctgacc tatttacaag 180
aacgcgaaca agctgaaaat agctggcgca aacgtttact gaagggtatt caagatcacg 240
ctttagatct ggttccgcgt ggctcccccg gccctccggg tccccccggt ccccccggtc 300
cgcccggtcc tcccggtcct cgcggtgaac aaggcccgca aggtttaccg ggtaaagacg 360
gtgaagccgg tgcacaaggt ccggctggtc cgatgggccc ggctggtttc ccgggcgagc 420
gtggtgagaa aggtgagccg ggcacccaag gtgctaaagg tgaccgtggt gaaaccggtc 480
ccgttggtcc tcgtggcgag cgcggtgaag ctggtcccgc tggtaaagac ggcgagcgcg 540
gtcccgttgg tccggccggc cccccgggcc cgcccggtcc gccgggcccc cccggtcccc 600
ccggttaagg atcc 614
<210> 21
<211> 280
<212> PRT
<213> 人工序列
<400> 21
His His His His His His Ala Asp Glu Gln Glu Glu Lys Ala Lys Val
1 5 10 15
Arg Thr Glu Leu Ile Gln Glu Leu Ala Gln Gly Leu Gly Gly Ile Glu
20 25 30
Lys Lys Asn Phe Pro Thr Leu Gly Asp Glu Asp Leu Asp His Thr Tyr
35 40 45
Met Thr Lys Leu Leu Thr Tyr Leu Gln Glu Arg Glu Gln Ala Glu Asn
50 55 60
Ser Trp Arg Lys Arg Leu Leu Lys Gly Ile Gln Asp His Ala Leu Asp
65 70 75 80
Leu Val Pro Arg Gly Ser Pro Gly Pro Pro Gly Pro Pro Gly Pro Pro
85 90 95
Gly Pro Pro Gly Pro Pro Gly Pro Arg Gly Glu Gln Gly Pro Gln Gly
100 105 110
Leu Pro Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Ala Gly Pro
115 120 125
Met Gly Pro Ala Gly Phe Pro Gly Glu Arg Gly Glu Lys Gly Glu Pro
130 135 140
Gly Thr Gln Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly Pro Val Gly
145 150 155 160
Pro Arg Gly Glu Arg Gly Glu Ala Gly Pro Ala Gly Lys Asp Gly Glu
165 170 175
Arg Gly Pro Val Gly Pro Ala Gly Pro Arg Gly Glu Gln Gly Pro Gln
180 185 190
Gly Leu Pro Gly Lys Asp Gly Glu Ala Gly Ala Gln Gly Pro Ala Gly
195 200 205
Pro Met Gly Pro Ala Gly Phe Pro Gly Glu Arg Gly Glu Lys Gly Glu
210 215 220
Pro Gly Thr Gln Gly Ala Lys Gly Asp Arg Gly Glu Thr Gly Pro Val
225 230 235 240
Gly Pro Arg Gly Glu Arg Gly Glu Ala Gly Pro Ala Gly Lys Asp Gly
245 250 255
Glu Arg Gly Pro Val Gly Pro Ala Gly Pro Pro Gly Pro Pro Gly Pro
260 265 270
Pro Gly Pro Pro Gly Pro Pro Gly
275 280
<210> 22
<211> 857
<212> DNA
<213> 人工序列
<400> 22
ccatgggcca tcatcatcac catcacgcag acgaacaaga agaaaaggcc aaagtgcgca 60
ccgaactgat tcaagaatta gcccaaggtt taggtggcat cgagaagaaa aactttccga 120
ctttaggcga tgaggatctg gaccacacct acatgaccaa gctgctgacc tatttacaag 180
aacgcgaaca agctgaaaat agctggcgca aacgtttact gaagggtatt caagatcacg 240
ctttagatct ggttccgcgt ggctcccccg gccctccggg tccccccggt ccccccggtc 300
cgcccggtcc tcccggtcct cgtggtgaac aaggtcctca aggtctgccc ggtaaggatg 360
gtgaagctgg tgcccaaggt ccggccggcc cgatgggccc cgctggtttt ccgggcgaac 420
gcggcgaaaa gggtgaaccg ggtacacaag gtgcaaaagg cgatcgtggc gagaccggtc 480
cggtcggtcc ccgcggtgaa cgtggcgagg ctggtcccgc tggtaaagat ggtgagcgtg 540
gcccggttgg tcccgctggt cctcgcggtg aacaaggccc gcaaggttta ccgggtaaag 600
acggtgaagc cggtgcacaa ggtccggctg gtccgatggg cccggctggt ttcccgggcg 660
agcgtggtga gaaaggtgag ccgggcaccc aaggtgctaa aggtgaccgt ggtgaaaccg 720
gtcccgttgg tcctcgtggc gagcgcggtg aagctggtcc cgctggtaaa gacggcgagc 780
gcggtcccgt tggtccggcc ggccccccgg gcccgcccgg tccgccgggc ccccccggtc 840
cccccggtta aggatcc 857
<210> 23
<211> 19
<212> DNA
<213> 人工序列
<400> 23
ctcgagggat ccgaattca 19
<210> 24
<211> 19
<212> DNA
<213> 人工序列
<400> 24
gagctccatg ggcactttg 19
Claims (14)
1.一种用于表达类I型胶原蛋白的蛋白单链，其特征在于，氨基酸序列如
所示；其中，V-domain的氨基酸序列如SEQ ID NO.1所示；(GPP)n中的5＜n≤30；CL-domain的氨基酸序列如SEQ ID NO.2~6任一序列所示。
2.根据权利要求1所述的蛋白单链，其特征在于，所述V-domain和(GPP)n之间通过LVPRGSP连接。
3.根据权利要求2所述的蛋白单链，其特征在于，所述V-domain前端具有6×His标签。
4.编码权利要求1~3任一所述蛋白单链的基因。
5.携带权利要求4所述基因的质粒或细胞。
6.根据权利要求5所述的质粒，其特征在于，包括：pColdIII系列或pET系列的质粒。
7.根据权利要求5所述的细胞，其特征在于，为大肠杆菌细胞，包括E. coli BL21、E. coli BL21（DE3）、E. coli JM109、E. coli DH5α或E. coli TOP10。
8.类I型胶原蛋白，其特征在于，由三条如
所示的蛋白单链围绕一个共同的中心轴盘绕，构成三螺旋结构；
其中，V-domain的氨基酸序列如SEQ ID NO.1所示；(GPP)n中的5＜n≤30；CL-domain的氨基酸序列如SEQ ID NO.2~6任一序列所示。
9.由权利要求8所述类I型胶原蛋白高聚自组装形成的胶原蛋白纤维。
10.一种类I型胶原蛋白纤维的制备方法，其特征在于，包括如下步骤：
（1）合成编码权利要求1所述类I型胶原蛋白的蛋白单链的基因；
（2）将步骤（1）所述基因与载体连接，转化至目的细胞中表达并纯化；
（3）向步骤（2）的纯化产物中加入胰蛋白酶，于20~25℃温度下反应至少6 h；
（4）将步骤（3）获得的胶原蛋白配制成浓度为0.1~1 mmol/L的溶液，于2℃~37℃静置。
11.根据权利要求10所述的方法，其特征在于，所述步骤（1）的基因的核苷酸序列如SEQID NO.13~15，17~18任一所示。
12.根据权利要求10所述的方法，其特征在于，所述步骤（4）的静置时间不少于24 h。
13.根据权利要求10所述的方法，其特征在于，所述步骤（4）是冻干后的胶原蛋白配制成浓度为0.5 mmol/L的溶液，于4℃~37℃静置至少2天。
14.权利要求1~3任一所述的类I型胶原蛋白单链，或权利要求4所述的基因，或权利要求5~7任一所述的质粒或细胞，或权利要求8所述的类I型胶原蛋白，或权利要求9所述的胶原蛋白纤维，或权利要求10~13任一所述的制备方法在制备含有胶原蛋白的产品方面的应用。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010327199.4A CN111333715B (zh) | 2020-04-23 | 2020-04-23 | 一种类i型胶原蛋白纤维的制备方法 |
| US17/082,525 US11639377B2 (en) | 2020-04-23 | 2020-10-28 | Preparation of type I collagen-like fiber and method for regulating and controlling the D-periodic of fiber thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010327199.4A CN111333715B (zh) | 2020-04-23 | 2020-04-23 | 一种类i型胶原蛋白纤维的制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111333715A CN111333715A (zh) | 2020-06-26 |
| CN111333715B true CN111333715B (zh) | 2021-04-13 |
Family
ID=71181080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010327199.4A Active CN111333715B (zh) | 2020-04-23 | 2020-04-23 | 一种类i型胶原蛋白纤维的制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111333715B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112521491B (zh) * | 2020-12-17 | 2022-06-10 | 江南大学 | 一种用于制备水凝胶的胶原蛋白及其制备方法 |
| CN113512094B (zh) * | 2021-06-29 | 2023-04-14 | 兰州大学 | 一种共价光交联多肽、共价光交联多肽自组装形成的胶原蛋白仿生材料 |
| CN117510618A (zh) * | 2023-11-06 | 2024-02-06 | 江西崇山生物制品有限公司 | 一种合成i型人源化胶原蛋白及其制备方法和应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371919A (zh) * | 2001-02-21 | 2002-10-02 | 范代娣 | 一种类人胶原蛋白及其生产方法 |
| CN105764920A (zh) * | 2013-09-09 | 2016-07-13 | 联邦科学工业研究组织 | 修饰的细菌胶原蛋白样蛋白 |
| WO2017020025A1 (en) * | 2015-07-29 | 2017-02-02 | Kiick Kristi | Thermoresponsive bioconjugates and their controlled delivery of cargo |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11236148B2 (en) * | 2016-06-14 | 2022-02-01 | Wisconsin Alumni Research Foundation | Method for the design of fibrillar collagen-mimetic peptide self-assemblies |
-
2020
- 2020-04-23 CN CN202010327199.4A patent/CN111333715B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371919A (zh) * | 2001-02-21 | 2002-10-02 | 范代娣 | 一种类人胶原蛋白及其生产方法 |
| CN105764920A (zh) * | 2013-09-09 | 2016-07-13 | 联邦科学工业研究组织 | 修饰的细菌胶原蛋白样蛋白 |
| WO2017020025A1 (en) * | 2015-07-29 | 2017-02-02 | Kiick Kristi | Thermoresponsive bioconjugates and their controlled delivery of cargo |
Non-Patent Citations (3)
| Title |
|---|
| Manipulation of the dually thermoresponsive behavior of peptide-based vesicles through modification of collagen-like peptide domains;Lucas C. Dunshee,et al.;《Bioeng Transl Med.》;20200131;第5卷(第1期);DOI: 10.1002/btm2.10145 * |
| Supramolecular Assembly Hydroxyproline-Lacking Collagen-Mimetic Peptidesof Electrostatically Stabilized，;Ohm D. Krishna，et al.;《Biomacromolecules》;20090914;第10卷(第9期);第2626-2631页 * |
| 胶原蛋白异源三聚体的理性设计;吕成等;《中国科学》;20190531;第49卷(第5期);第615-624页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111333715A (zh) | 2020-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111333715B (zh) | 一种类i型胶原蛋白纤维的制备方法 | |
| CN111704663B (zh) | 一种胶原蛋白水凝胶的制备方法 | |
| CN111944057B (zh) | 一种重组人胶原蛋白肽及其应用 | |
| CN108794639B (zh) | 一种重组纤连蛋白及其应用 | |
| US9382310B2 (en) | Expression of triple-helical collagen-like products in E. coli | |
| CN113717290B (zh) | 一种复合透皮重组纤连蛋白及其应用 | |
| CN114805551B (zh) | 一种重组iii型胶原蛋白及其制备方法 | |
| CN114106150B (zh) | 重组胶原蛋白、制备方法及其应用 | |
| KR20120076346A (ko) | 실크 도프의 제조 방법 | |
| GB2485385A (en) | Trimeric fusion protein comprising collagen and a prokaryotic/ viral trimerisation domain | |
| CN114853881B (zh) | 一种重组人源融合胶原蛋白及其高效羟基化方法与应用 | |
| CN115521373A (zh) | 一种三螺旋重组人源化i型胶原蛋白、制备方法及其应用 | |
| US20040132978A1 (en) | Method for purifying and recovering silk proteins in soluble form and uses thereof | |
| CN111499729B (zh) | 一种调控类i型胶原蛋白纤维条纹周期长度的方法 | |
| US9109047B2 (en) | High molecular ordered fibrilar structures, method for their preparation and uses thereof | |
| CN108948208A (zh) | 一种可注射自修复水下蛋白及其用途 | |
| US11639377B2 (en) | Preparation of type I collagen-like fiber and method for regulating and controlling the D-periodic of fiber thereof | |
| CN108753183A (zh) | 一种活体水下粘合材料及其用途 | |
| CN115947827A (zh) | 一种重组胶原蛋白及其在软骨修复基质中的用途 | |
| WO2011046519A1 (en) | Polypeptide material composed of elastin-like segments and coiled coil segments | |
| CN117186210A (zh) | 胶原域、胶原蛋白、重组胶原蛋白表达菌及应用 | |
| CN113004425A (zh) | 人表皮生长因子融合功能多肽的蛋白及其制备方法与应用 | |
| CN114605516B (zh) | 具有自组装特性和生物矿化功能的藤壶胶蛋白20k衍生多肽、其制备方法和应用 | |
| CN117466992B (zh) | 一种纤连蛋白突变体及其制备和应用 | |
| EP4286397A1 (en) | Hydrogel-forming proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |